MARKET

ENSC

ENSC

Ensysce Biosciences Inc
NASDAQ
0.5140
-0.0135
-2.56%
Pre Market: 0.4900 -0.024 -4.67% 07:48 03/31 EDT
OPEN
0.5410
PREV CLOSE
0.5275
HIGH
0.5410
LOW
0.5002
VOLUME
5.01K
TURNOVER
32.22K
52 WEEK HIGH
4.850
52 WEEK LOW
0.3144
MARKET CAP
1.82M
P/E (TTM)
-0.0809
1D
5D
1M
3M
1Y
5Y
1D
Ensysce Biosciences Q4 EPS $(0.75) Misses $(0.70) Estimate, Sales $1.882M Beat $500.000K Estimate
Benzinga · 18h ago
Ensysce Biosciences Q4 net loss narrows to $2.8 mln
Reuters · 18h ago
Ensysce Biosciences GAAP EPS of -$0.75 beats by $0.51
Seeking Alpha · 18h ago
ENSYSCE BIOSCIENCES Q4 NET INCOME USD -2.8 MILLION
Reuters · 18h ago
Weekly Report: what happened at ENSC last week (0323-0327)?
Weekly Report · 1d ago
Ensysce Biosciences director Lee Rauch resigns from board amid retention package dispute
Reuters · 1d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/24 12:05
Ensysce Biosciences Corrects Series B Preferred Stock Designation
TipRanks · 03/23 12:30
More
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Webull offers Ensysce Biosciences Inc stock information, including NASDAQ: ENSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENSC stock methods without spending real money on the virtual paper trading platform.